Clinical Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, ul. Ceglana 35, 40-925, Katowice, Poland.
Inflammation. 2010 Oct;33(5):320-4. doi: 10.1007/s10753-010-9188-1.
Dehydroepiandrosterone (DHEA) is considered as an important immunomodulating and anti-inflammatory hormone. Despite the continuing interest in DHEA replacement therapy, our knowledge of its effects upon asthma is very limited. DHEA is able to reverse cytokine imbalances associated with asthma, may prevent and attenuate allergic inflammation in airways, and does not possess the undesirable side effects of glucocorticoids; therefore, it may be potentially applied in the treatment of asthma. The steroid-sparing effect observed with DHEA clinically could appear especially favorable in asthmatic patients receiving oral treatment and those inhaling high doses of glucocorticoids. In addition, DHEA and its analogs might prove useful in reversing relative glucocorticoids insensitivity in patients with corticosteroid-resistant asthma. In this review we have focused specifically on DHEA's role in asthma.
脱氢表雄酮(DHEA)被认为是一种重要的免疫调节和抗炎激素。尽管人们对 DHEA 替代疗法持续关注,但我们对其在哮喘中的作用知之甚少。DHEA 能够逆转与哮喘相关的细胞因子失衡,可能预防和减轻气道中的过敏炎症,并且没有糖皮质激素的不良副作用;因此,它可能有潜力应用于哮喘的治疗。临床上观察到的 DHEA 具有类固醇节约作用,在接受口服治疗和吸入高剂量糖皮质激素的哮喘患者中可能显得特别有利。此外,DHEA 及其类似物可能在逆转皮质激素抵抗性哮喘患者的相对皮质激素不敏感方面证明有用。在这篇综述中,我们专门关注了 DHEA 在哮喘中的作用。